Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
92.25
-2.10 (-2.23%)
Feb 21, 2025, 4:00 PM EST - Market closed
Blueprint Medicines Employees
Blueprint Medicines had 649 employees as of December 31, 2024. The number of employees decreased by 6 or -0.92% compared to the previous year.
Employees
649
Change (1Y)
-6
Growth (1Y)
-0.92%
Revenue / Employee
$784,012
Profits / Employee
-$103,373
Market Cap
5.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 649 | -6 | -0.92% |
Dec 31, 2023 | 655 | 14 | 2.18% |
Dec 31, 2022 | 641 | 146 | 29.49% |
Dec 31, 2021 | 495 | 66 | 15.38% |
Dec 31, 2020 | 429 | 46 | 12.01% |
Dec 31, 2019 | 383 | 166 | 76.50% |
Dec 31, 2018 | 217 | 68 | 45.64% |
Dec 31, 2017 | 149 | 43 | 40.57% |
Dec 31, 2016 | 106 | 25 | 30.86% |
Dec 31, 2015 | 81 | 20 | 32.79% |
Dec 31, 2014 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BPMC News
- 9 days ago - Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - PRNewsWire
- 17 days ago - Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 - PRNewsWire
- 5 weeks ago - Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PRNewsWire
- 2 months ago - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - PRNewsWire
- 3 months ago - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs - Seeking Alpha
- 3 months ago - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Benzinga